Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Merus N.V. CS (MRUS)

Merus N.V. CS (MRUS)
15.30 x 2 46.00 x 5
Post-market by (Cboe BZX)
38.62 -0.94 (-2.38%) 04/10/25 [NASDAQ]
15.30 x 2 46.00 x 5
Post-market 38.62 unch (unch) 16:00 ET
Quote Overview for Thu, Apr 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
35.53
Day High
39.24
Open 39.24
Previous Close 39.56 39.56
Volume 1,002,900 1,002,900
Avg Vol 832,720 832,720
Stochastic %K 24.93% 24.93%
Weighted Alpha -25.79 -25.79
5-Day Change -3.11 (-7.45%) -3.11 (-7.45%)
52-Week Range 33.19 - 61.61 33.19 - 61.61
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,733,200
  • Shares Outstanding, K 69,090
  • Annual Sales, $ 36,130 K
  • Annual Income, $ -215,330 K
  • EBIT $ -272 M
  • EBITDA $ -270 M
  • 60-Month Beta 1.02
  • Price/Sales 66.71
  • Price/Cash Flow N/A
  • Price/Book 3.69

Options Overview Details

View History
  • Implied Volatility 77.79% ( -0.94%)
  • Historical Volatility 69.02%
  • IV Percentile 86%
  • IV Rank 36.23%
  • IV High 147.11% on 05/16/24
  • IV Low 38.41% on 01/22/25
  • Put/Call Vol Ratio 0.33
  • Today's Volume 20
  • Volume Avg (30-Day) 468
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 8,377
  • Open Int (30-Day) 6,664

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.17
  • Number of Estimates 7
  • High Estimate -0.86
  • Low Estimate -1.36
  • Prior Year -0.59
  • Growth Rate Est. (year over year) -98.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.19 +16.36%
on 04/09/25
Period Open: 46.75
49.88 -22.57%
on 03/13/25
-8.13 (-17.39%)
since 03/10/25
3-Month
33.19 +16.36%
on 04/09/25
Period Open: 43.85
49.88 -22.57%
on 03/13/25
-5.23 (-11.93%)
since 01/10/25
52-Week
33.19 +16.36%
on 04/09/25
Period Open: 41.74
61.61 -37.32%
on 05/24/24
-3.12 (-7.47%)
since 04/10/24

Most Recent Stories

More News
Merus N.V. Announces First Patient Dosed in Phase 2 Trial of Petosemtamab for Metastatic Colorectal Cancer

Merus N.V. has dosed the first patient in a phase 2 trial of petosemtamab for metastatic colorectal cancer.Quiver AI SummaryMerus N.V. has announced the dosing of the first patient in a phase 2 trial assessing...

MRUS : 38.62 (-2.38%)
Merus N.V. Updates on Petosemtamab Clinical Trials in Head and Neck Squamous Cell Carcinoma and Metastatic Colorectal Cancer

Merus announces ongoing trials of petosemtamab for head and neck and colorectal cancers, with data updates expected in 2025.Quiver AI SummaryMerus N.V. announced interim clinical results from its ongoing...

MRUS : 38.62 (-2.38%)
Merus N.V. Receives FDA Approval for BIZENGRI®: First Targeted Therapy for NRG1+ Advanced Pancreatic Adenocarcinoma and NSCLC

BIZENGRI® is the FDA-approved therapy for advanced pancreatic adenocarcinoma and NSCLC with NRG1 gene fusions, offering new treatment options.Quiver AI SummaryMerus N.V. has announced that the U.S. FDA...

MRUS : 38.62 (-2.38%)
Merus N.V. Announces Positive Phase 2 Interim Data for Petosemtamab Monotherapy in Second-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Petosemtamab shows promising results in treating recurrent/metastatic HNSCC; full data to be discussed on December 7.Quiver AI SummaryMerus N.V. announced the interim data from a Phase 2 trial of petosemtamab...

MRUS : 38.62 (-2.38%)
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates

/CNW/ -- USA News Group – Pancreatic cancer is among the deadliest cancers, prompting researchers to focus on early detection to improve survival rates. Johns...

ONCY : 0.5001 (-3.77%)
HALO : 57.70 (-4.86%)
CADL : 4.77 (-6.29%)
MRUS : 38.62 (-2.38%)
RHHBY : 36.8600 (-0.65%)
ONC.TO : 0.70 (-5.41%)
Biotech Innovations Poised to Transform Pancreatic Cancer Treatment and Patient Outcomes

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – Pancreatic cancer is among the...

ONCY : 0.5001 (-3.77%)
ONC.TO : 0.70 (-5.41%)
RHHBY : 36.8600 (-0.65%)
HALO : 57.70 (-4.86%)
CADL : 4.77 (-6.29%)
MRUS : 38.62 (-2.38%)
Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates

/CNW/ -- USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic...

ONCY : 0.5001 (-3.77%)
CADL : 4.77 (-6.29%)
AZN : 64.87 (-2.83%)
MRUS : 38.62 (-2.38%)
LTRN : 3.04 (+3.40%)
ONC.TO : 0.70 (-5.41%)
Biotech Developers Pioneer New Treatments, Aiming to Reduce Pancreatic Cancer Fatalities in 2024

USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic cancer patients through earlier detection, as according...

ONCY : 0.5001 (-3.77%)
ONC.TO : 0.70 (-5.41%)
CADL : 4.77 (-6.29%)
AZN : 64.87 (-2.83%)
MRUS : 38.62 (-2.38%)
LTRN : 3.04 (+3.40%)
Pancreatic Cancer Battle Intensifies with Biotech Sector's Advanced Treatments

USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage pancreatic cancer with 97% accuracy. This breakthrough...

ONCY : 0.5001 (-3.77%)
ONC.TO : 0.70 (-5.41%)
RHHBY : 36.8600 (-0.65%)
MRUS : 38.62 (-2.38%)
MGNX : 1.2500 (-1.57%)
IMRX : 1.2400 (-3.88%)
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END

ONCY : 0.5001 (-3.77%)
ONC.TO : 0.70 (-5.41%)
PYXS : 0.9073 (-7.93%)
AZN : 64.87 (-2.83%)
LLY : 720.91 (-4.35%)
MRUS : 38.62 (-2.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is...

See More

Key Turning Points

3rd Resistance Point 43.77
2nd Resistance Point 41.51
1st Resistance Point 40.06
Last Price 38.62
1st Support Level 36.35
2nd Support Level 34.09
3rd Support Level 32.64

See More

52-Week High 61.61
Fibonacci 61.8% 50.75
Fibonacci 50% 47.40
Fibonacci 38.2% 44.05
Last Price 38.62
52-Week Low 33.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar